With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...

Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...

The Philippines is not only known for its stunning landscapes and warm-hearted people but also for its brilliant minds that ...

Year 2015-16 and 2016-17 with the issues involved relating to levy of penalty under section 272A(2)(g) and section 271C of the Income Tax Act, 1961 (“the Act” for short). All the appeals arise from ...

The Oklahoma high school basketball playoffs continue this week, with the OSSAA Class 5A state tournament quarterfinals ...

DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an inhibitor of the ...